A5058442171- Coronary Interventions and Diagnostics
- Cardiomyopathy and Myosin Studies
- Cardiac Imaging and Diagnostics
- Mechanical Circulatory Support Devices
- Acute Myocardial Infarction Research
- Cardiac Arrest and Resuscitation
- Cardiovascular Function and Risk Factors
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Structural Anomalies and Repair
- Cardiac Valve Diseases and Treatments
- Venous Thromboembolism Diagnosis and Management
- Congenital Heart Disease Studies
- Cardiac Arrhythmias and Treatments
- Cardiovascular Effects of Exercise
- Heart Failure Treatment and Management
- Cardiac pacing and defibrillation studies
- Atrial Fibrillation Management and Outcomes
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiovascular and Diving-Related Complications
- Peripheral Artery Disease Management
- Infective Endocarditis Diagnosis and Management
- Vascular Procedures and Complications
- Cardiac electrophysiology and arrhythmias
- Lipoproteins and Cardiovascular Health
- Cardiac Ischemia and Reperfusion
Tufts Medical Center
2015-2024
Tufts University
2004-2023
American Heart Association
2021
American College of Cardiology
2021
Heart Rhythm Society
2021
European Society of Cardiology
2021
University Medical Center
2010-2020
Brigham and Women's Hospital
2005-2020
Association of Chartered Certified Accountants
2020
Beth Israel Deaconess Medical Center
2016
In ST-segment-elevation myocardial infarction (STEMI), infarct size correlates directly with heart failure and mortality. Preclinical testing has shown that, in comparison reperfusion alone, mechanically unloading the left ventricle (LV) before reduces that 30 minutes of activates a cardioprotective program limits injury. The DTU-STEMI pilot trial (Door-To-Unload STEMI Pilot Trial) represents first exploratory study whether LV delayed patients without cardiogenic shock is safe feasible.In...
There is little information regarding long-term mortality comparing the 2 most common procedures for septal reduction obstructive hypertrophic cardiomyopathy (HCM), alcohol ablation (ASA), and myectomy.This study sought to compare of patients with HCM following myectomy or ASA.We evaluated outcomes 3,859 who underwent ASA in 3 specialized centers. All-cause was primary endpoint study.In cohort, 585 (15.2%) ASA, 3,274 (84.8%) myectomy. Patients undergoing were significantly older (median age:...
Importance Drug-coated balloons offer a potentially beneficial treatment strategy for the management of coronary in-stent restenosis. However, none have been previously evaluated or approved use in circulation United States. Objective To evaluate whether paclitaxel-coated balloon is superior to an uncoated patients with restenosis undergoing percutaneous intervention. Design, Setting, and Participants AGENT IDE, multicenter randomized clinical trial, enrolled 600 (lesion length...
Right ventricular dysfunction (RVD) is a major cause of morbidity and mortality in the setting acute inferior wall myocardial infarction (IWMI), early detection may improve clinical outcomes. We defined novel hemodynamic index, pulmonary artery pulsatility index (PAPi), explored whether PAPi correlates with severe RVD IWMI.From 2008 to 2010, we identified 20 patients presenting angiographically confirmed proximal right coronary occlusion suspected (sRVD) as by instability, profound...
Several trials support the usefulness of disease management (DM) for improving clinical outcomes in heart failure (HF). Most these studies are limited by small sample size; absence concurrent, randomized controls; follow-up; restriction to urban academic centers; and low baseline use effective medications.We performed a prospective, assessment effectiveness HF DM delivered 90 days across diverse provider network heterogeneous population 200 patients with high approved pharmacotherapy. During...
Thrombin-dependent platelet activation is heightened in the setting of percutaneous coronary intervention and may cause arterial thrombosis with consequent myocardial necrosis. Given high incidence adverse effects patients acute syndromes, there remains an unmet need for development new therapeutics that target without unduly affecting hemostasis. The thrombin receptor, PAR1, has recently emerged as a promising therapeutic syndromes.We report first-in-class intracellular PAR1 inhibitor...
Background: The outcome of medically refractory patients with obstructive hypertrophic cardiomyopathy treated according to the American College Cardiology/American Heart Association consensus guideline recommendations is not known. objectives this study were define short- and long-term outcomes undergoing alcohol septal ablation (ASA) surgical myectomy (SM) patient management in accordance these guidelines, as well quantify procedural risk burden comorbid conditions at time treatment....
Bivalirudin, a direct thrombin inhibitor, is widely used adjunctive therapy in patients undergoing percutaneous intervention (PCI). Thrombin highly potent agonist of platelets and activates the protease-activated receptors, PAR1 PAR4, but it not known whether bivalirudin exerts antiplatelet effects PCI patients. We tested hypothesis that acts as an agent by preventing activation PARs on platelet surface.The effect function systemic levels was assessed elective PCI. Mean plasma were 2.7±0.5...
Reducing congestion remains a primary target of therapy for acutely decompensated heart failure. The VENUS-HF EFS (VENUS-Heart Failure Early Feasibility Study) is the first clinical trial testing intermittent occlusion superior vena cava with preCARDIA system, catheter mounted balloon and pump console, to improve decongestion in failure.In multicenter, prospective, single-arm exploratory safety feasibility trial, 30 patients failure were assigned 12 or 24 hours. outcome was composite major...
Epidemiology data for lower-extremity arterial thromboembolism (LET) are limited and may result from either acute limb ischemia or an exacerbation of critical ischemia. Given marked changes in both diagnosis therapy over the last 2 decades, we hypothesized that this time period would have witnessed reductions incidence in-hospital mortality LET.Data 1988 through 2007 National Hospital Discharge Survey were analyzed. All admissions patients with LET extracted, respective International...
Protease-activated receptor-1 (PAR1) is classically activated by thrombin and critical in controlling the balance of hemostasis thrombosis. More recently, it has been shown that noncanonical activation PAR1 matrix metalloprotease-1 (MMP1) contributes to arterial However, role long-term development atherosclerosis unknown, regardless protease agonist.We found plasma MMP1 was significantly correlated (R=0.33; P=0.0015) with coronary atherosclerotic burden as determined angiography 91 patients...
Bleeding complications and acute limb ischemia (ALI) are devastating vascular in patients with ST-segment elevation myocardial infarction (STEMI). Cardiogenic shock (CS) can further increase this risk due to multiorgan failure. In the contemporary era, percutaneous mechanical circulatory support is commonly used for management of CS. We hypothesized that may be an important determinant clinical outcomes CS STEMI (CS-STEMI).We evaluated 10-year national trends, resource utilization bleeding...
Abstract Objectives: We investigated the prevalence of migraine in patients with patent foramen ovale (PFO), and effect PFO closure on symptoms medications. Background: Studies have shown an association between PFO. Data recently suggested a reduction following closure. Most these studies had no controls. Methods: Subjects were divided into three groups: No (Controls, n = 65), intervention (“Open PFO”, 63), treated percutaneous (“Closed 41). measured frequency, severity, impact quality life...